期刊文献+

免疫活化血小板对人脐静脉内皮细胞COX-2及PPAR-α表达与活性的影响及LDL的作用 被引量:2

Effects of immune-activated platelets and LDL on expression and activity of COX-2 and PPAR-α in HUVECs
下载PDF
导出
摘要 目的:观察免疫活化血小板对人脐静脉内皮细胞(HUVECs)环氧合酶2(COX-2)及过氧化物酶体增殖物活化受体α(PPAR-α)表达及活性的影响,并探讨低密度脂蛋白(LDL)对其作用。方法:利用腺苷二磷酸(ADP)刺激血小板免疫活化,然后利用免疫活化血小板与HUVECs加或不加LDL共孵育,利用实时定量RT-PCR、Westernblotting分别检测HUVECsCOX-2及PPAR-αmRNA及其蛋白的表达,ELISA法检测PGE2浓度反映COX-2活性、核因子活性检测试剂盒检测PPAR-α活性。结果:血小板活化组COX-2及PPAR-αmRNA表达量较血小板对照组均有较明显升高(1.49±0.27vs0.68±0.21,1.45±0.21vs1.17±0.16,均P<0.01);血小板活化组COX-2及PPAR-α蛋白表达量较血小板对照组亦有较明显升高(1.600±0.145vs0.700±0.073,1.630±0.143vs0.960±0.073,均P<0.01),血小板活化组孵育液中PGE2浓度较血小板对照组明显升高[(42.46±5.57)ng/Lvs(23.73±2.53)ng/L,P<0.01],但血小板活化组PPAR-α活性较血小板对照组无明显变化;LDL本身无明显增加HUVECsCOX-2及PPAR-α的表达及活性,但其能增加免疫活化血小板的这一作用。结论:免疫活化血小板显著促进HUVECsCOX-2表达及活性增加,亦能显著促进HUVECsPPAR-α表达,但并不改变PPAR-α活性;一般浓度的LDL并不对HUVECsCOX-2、PPAR-α的表达及活性产生影响,但能促进免疫活化血小板对内皮细胞的这一作用。 AIM : To observe the effect of immune - activated platelets and low - density lipoprotein cholesterol (LDL) on the expression and activity of cyclooxygenase -2 (COX -2) and peroxisome proliferator activated receptor α (PPAR -α) in human umbilical vein endothelial cells (HUVECs) treated with activated platelets and LDL. METHODS: The platelets were activated by ADP. The co - culture system of HUVECs with immune activated platelets and/or LDL were established. The activity of COX -2 and expression of PPAR -α at mRNA and protein levels in HUVECs were detected by RT - PCR and Western blotting. The concentration of PGE2 was measured by ELISA for representing the COX - 2 activity. The PPAR - α activity was determined by a nuclear factor assay kit. RESULTS : The COX - 2 activity and mRNA expression of PPAR - α, the protein levels of COX - 2 and PPAR - α and PGE2 concentration in activated platelets group were significant higher than those in un - activated platelets group (all P 〈 0.01 ). No difference of PPAR - α binding activity was observed between two groups. LDL didn't affect the COX -2 activity and PPAR-α expression, but significantly promoted the stimulating effect of immune - activated platelets. CONCLUSION: Immune - activated platelets significantly promote COX -2 activity and PPAR -α expression in HUVECs, but don't change the PPAR -α binding activity. LDL at general concentration does not affect the expression and activity of COX - 2 and PPAR - α, but promote the effect of activated platelets on HUVECs.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2010年第7期1325-1330,共6页 Chinese Journal of Pathophysiology
基金 江西省研究生创新专项基金资助项目 国家科技部支撑计划资助项目(No.2008BAI68B02)
关键词 免疫活化血小板 动脉粥样硬化 环氧合酶2 过氧化物酶体增殖物活化受体α 人脐静脉内皮细胞 Immune - activated platelets Atherosclerosis Cyclooxygenase - 2 Peroxisome proliferator activated receptor- α Human umbilical vein endothelial cells
  • 相关文献

参考文献16

  • 1Cipollone F,Rocca B,Patrono C.Cyclooxygenase-2 expression and inhibition in atherothrombosis[J].Arterioscler Thromb Vasc Biol,2004,24(2):246-255.
  • 2Mosheimer BA,Kaneider NC,Feistritzer C,et al.CD40 -ligand-dependent induction of COX-2 gene expression in endothelial cells by activated phtelets:inhibitory effects of atorvastatin[J].Blood Coagul Fibrinolysis,2005,16(2):105-110.
  • 3McGeer PL,McGeer EG,Yasojima K.Expression of COX -1 and COX-2 in atheroaclerotic plaques[J].Exp Gerontol,2002,37(7):925-929.
  • 4Meir KS,Leitetsdorf E.Atherosclerosis in the apolipoprotein E-deficient mouse:a decade of progress[J].Arterioseler Thromb Vasc Biol,2004,24(6):1006-1014.
  • 5Rott D,Zhu J,Bumett MS,et al.Effects of MF-tricyclic,a selective cyclooxygenase-2 inhibitor,on atherosclerotic progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knock out mice[J].J Am Coll Cardiol,2003,41(10):1812-1819.
  • 6Paramo JA,Rodriguez JA,Beloqui O,et al.Monocyte cyclooxygenase-2 activity:a new therapeutic target for atheroscleresis[J].Curr Drug Targets Cardiovasc Haemato Disord,2005,5(4):303-311.
  • 7Cipollone F.COX-2 and prostaglandins in atherosclerosis[J].Lupus,2005,14(9):756-759.
  • 8Orbe J,Beloqui O,Rodriguez JA,et al.Protective effect of the G765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors[J].Clin Chim Acta,2006,368(1-2):138-143.
  • 9Seloqui O,Paramo JA,Orbe J,et al.Monocyte cyclooxygenase-2 overactivity:a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors[J].Eur Heart J,2005,26(2):153-158.
  • 10Grosser T,Fries S,FitzGerald GA.J Biological basis for the cardiovascular consequences of COX-2 inhibition:therapeutic challenges and opportunities[J].Clin Invest,2006,116(1):4-15.

二级参考文献14

  • 1蒋青松,黄燮南,周岐新,杨贵忠,戴支凯,吴芹,石京山.钙调神经磷酸酶信号通路参与PGF_(2α)诱导的心肌细胞肥大[J].中国病理生理杂志,2007,23(7):1272-1276. 被引量:9
  • 2Saunders J, Mathewkutty S, Drazner MH, et al. Cardiomyopathy in type 2 diabetes: update on pathophysioiogical mechanisms[J]. Herz, 2008, 33(3): 184- 190.
  • 3Kuethe F, Sigusch HH, Bornstein SR, et al. Apoptosis in patients with dilated cardiomyopathy and diabetes: a feature of diabetic cardiomyopathy [ J ]. Horm Metab Res, 2007, 39 (9) : 672 - 676.
  • 4Movahed MR. Diabetes as a risk factor for cardiac conduction defects [ J ]. Diabetes Obes Metab, 2007, 9 (3) : 276 -281.
  • 5Bell D, McDermott BJ. Effects of rosiglitazone and interactions with growth -regulating factors inventricular cell hypertrophy[ J ]. Eur J Pharmacol, 2005, 508 (1): 69- 76.
  • 6Liao Y, Takashima S, Zhao H, et al. Control of plasma glucose with alpha - glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice [ J ]. Cardiovasc Res, 2006, 70 ( 1 ) : 107 - 116.
  • 7Rivero A, Mora C, Muros M, et al. Pathogenic perspectives for the role of inflammation in diabetic nephropathy [J]. Clin Sci, 2009, 116(6) : 479 -492.
  • 8Youssef J, Badr M. Role of peroxisome proliferator - activated receptors in inflammation control[ J]. J Biomed Biotechnol, 2004, 169(3) : 156 - 166.
  • 9Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism [ J ]. Trends Cardiovasc Med, 2000, 10(6) : 238 -245.
  • 10Yu Z, Schneider C, Boeglin WE, et al. Epidermal lipoxygenase products of the hepoxilin pathway selectively activate the nuclear receptor PPARalpha [ J 1. Lipids, 2007, 42(6) : 491 -497.

共引文献2

同被引文献29

  • 1李传保,卜培莉,张运,公茂磊,侯晓阳,郝明秀,赵学强,孟晓.非诺贝特对自发性高血压大鼠心肌重构及NF-κB表达的影响[J].山东大学学报(医学版),2007,45(1):46-49. 被引量:5
  • 2Golightly E, Jabbour H N, Norman J E. Endocrine im- mune interactions in human parturition [J]. Mol Cell En- docrinol, 2011, 335 ( 1 ) :52-59.
  • 3Challis J R, Lockwood C J, Myatt J E, et al. Inflamma- tion and pregnancy[J]. Reprod Sci, 2009, 16(2) :206- 215.
  • 4Planavila A, Iglesias R, Giralt M, et al. Sirtl acts in as- sociation with PPARalpha to protect the heart from hyper- trophy, metabolic dysregulation, and inflammation [ J ]. Cardiovasc Res, 2011, 90(2) :276-284.
  • 5Eberhardt W, Akoolel S, Rebhan J, et al. Inhibition of cytokine-induced matrix metallopro-teinase 9 expression by peroxisome proliferator-activated receptor alpha ago- nists is indirect and due to a NO-mediated reduction of mRNA stability[J]. J Biol Chem, 2002, 277 ( 36 ) : 33518-33528.
  • 6Berry E B, Eykholt R, Helliwell R J, et al. Peroxisome proliferator-activated receptor isoform expression changes in human gestational tissues with labor at term[J]. Mol Pharrnacol, 2003, 64(6) :1586-1590.
  • 7Bogacka I, Bogacki M. The quantitative expression of peroxisome proliferator activated receptor (PPAR) genes in porcine endometrium through the estrous cycle and ear- ly pregnancy[J]. J Physiol Pharmacol, 2011, 62 ( 5 ) : 559-565.
  • 8Challis J R G, Matthews S G, Gibb W, et al. Endocrine and paracrine regulation of birth at term and preterm[J].Endocr Rev, 2000, 21 (5) :514-550.
  • 9Yessoufou A, Hichami A, Besnard P, et al. Peroxisome proliferator-activated receptor alpha deficiency increases the risk of maternal abortion and neonatal mortality in mu- rine pregnancy with or without diabetes mellitus : Modula- tion of T cell differentiation [J].Endocrinology, 2006, 147(9) :4410-4418.
  • 10Lindstrom T M. P R Bennett. 15-Deoxy-delta 12,14-prostaglandin j2 inhibits-induced inter- leukin-1 beta nu- clear factor- kappa b in human amnion and myometrial cells : mechanisms and implications[J].J Clin Endocri- nol Metab, 2005, 90(6) :3534-3543.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部